Butylone
Studies and references cited across this article, graded by evidence strength.
Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.
Data points an editor reviewed and accepted for publication.
Value Provenance
Dosing
oraltrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 25 mg | 25 mg | low |
| Low | 40–80 mg | 40–80 mg | low |
| Common | 80–150 mg | 80–150 mg | low |
| Strong | 150–250 mg | 150–250 mg | low |
| Heavy | 250+ mg | 250+ mg | low |
| Editorial | No published human dose-response data for butylone. Values inferred from community-curated sources (existing database values carried forward from Psychedex seed data, originally sourced from harm reduction community consensus). Ranges widened slightly from methylone to account for butylone's lower transporter affinity. These require editorial verification. | ||
ReasoningReasoningNo published human dose-response data for butylone. Values inferred from community-curated sources (existing database values carried forward from Psychedex seed data, originally sourced from harm reduction community consensus). Ranges widened slightly from methylone to account for butylone's lower transporter affinity. These require editorial verification. Evidence basis: community_consensus_small | |||
insufflatedtrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 15 mg | 15 mg | low |
| Low | 25–60 mg | 25–60 mg | low |
| Common | 60–120 mg | 60–120 mg | low |
| Strong | 120–200 mg | 120–200 mg | low |
| Heavy | 200+ mg | 200+ mg | low |
| Editorial | No published insufflated dose data for butylone. Inferred from oral doses with typical ~75-80% bioavailability adjustment for insufflated cathinones (class-level assumption from methylone/mephedrone). Wider uncertainty than oral values. | ||
ReasoningReasoningNo published insufflated dose data for butylone. Inferred from oral doses with typical ~75-80% bioavailability adjustment for insufflated cathinones (class-level assumption from methylone/mephedrone). Wider uncertainty than oral values. Evidence basis: structural_analogy | |||
Duration
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Offsettrace | 45–90 minutes | 45–90 minutes | low |
| Editorial | Inferred from total duration minus onset/come-up/peak estimates. No published data. | ||
ReasoningReasoningInferred from total duration minus onset/come-up/peak estimates. No published data. Evidence basis: structural_analogy | |||
| Onsettrace | 15–60 minutes | 15–60 minutes | low |
| Editorial | Community-reported onset time from existing database values. Consistent with LogP 1.34 and confirmed high BBB permeability. No controlled PK data. | ||
ReasoningReasoningCommunity-reported onset time from existing database values. Consistent with LogP 1.34 and confirmed high BBB permeability. No controlled PK data. Evidence basis: community_consensus_small | |||
| Come uptrace | 15–30 minutes | 15–30 minutes | low |
| Editorial | Inferred from methylone come-up profile and community reports. No published data. | ||
ReasoningReasoningInferred from methylone come-up profile and community reports. No published data. Evidence basis: structural_analogy | |||
| Peaktrace | 60–90 minutes | 60–90 minutes | low |
| Editorial | Inferred from methylone peak duration and community reports of 3-5 hour total duration. No published data. | ||
ReasoningReasoningInferred from methylone peak duration and community reports of 3-5 hour total duration. No published data. Evidence basis: structural_analogy | |||
| Totaltrace | 3–5 hours | 3–5 hours | low |
| Editorial | Community-reported total subjective duration from existing database values. Plausible given comparison with methylone (similar PK expected). No controlled PK measurement confirms this. | ||
ReasoningReasoningCommunity-reported total subjective duration from existing database values. Plausible given comparison with methylone (similar PK expected). No controlled PK measurement confirms this. Evidence basis: community_consensus_small | |||
| After effectstrace | 2–4 hours | 2–4 hours | low |
| Editorial | Inferred from stimulant cathinone class profile. Residual stimulation and mood effects persist beyond subjective experience window. | ||
ReasoningReasoningInferred from stimulant cathinone class profile. Residual stimulation and mood effects persist beyond subjective experience window. Evidence basis: structural_analogy | |||
insufflated
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 5–15 minutes | 5–15 minutes | low |
| Editorial | Inferred from insufflated cathinone class onset (rapid nasal absorption). No published data for butylone specifically. | ||
ReasoningReasoningInferred from insufflated cathinone class onset (rapid nasal absorption). No published data for butylone specifically. Evidence basis: structural_analogy | |||
| Totaltrace | 2–4 hours | 2–4 hours | low |
| Editorial | Inferred from oral duration with typical reduction for insufflated route (shorter total, faster onset). Class-level cathinone pattern. | ||
ReasoningReasoningInferred from oral duration with typical reduction for insufflated route (shorter total, faster onset). Class-level cathinone pattern. Evidence basis: structural_analogy | |||
Safety
Toxicity Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Acute | moderate | moderate | medium |
| Chronic | moderate | moderate | medium |
| Organs Affected | liver, cardiovascular, brain | liver, cardiovascular, brain | medium |
| Editorial | Classified as moderate (not high): fatal cases involve intentional overdose (20 mg/L) or combined cathinone ingestion, not recreational doses alone. Hepatotoxicity and neurotoxicity data are in vitro only. No in vivo chronic toxicity studies exist; chronic rating based on class-level cathinone cardiovascular and neurotoxicity evidence with evidence discount applied. | ||
ReasoningReasoningClassified as moderate (not high): fatal cases involve intentional overdose (20 mg/L) or combined cathinone ingestion, not recreational doses alone. Hepatotoxicity and neurotoxicity data are in vitro only. No in vivo chronic toxicity studies exist; chronic rating based on class-level cathinone cardiovascular and neurotoxicity evidence with evidence discount applied. Evidence basis: published_case_series | |||
Dependence Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Physical | low | low | low |
| Psychological | moderate | moderate | low |
| Compulsive Redosing | moderate | moderate | low |
| Dose Escalation | moderate | moderate | low |
| Editorial | No butylone-specific self-administration, CPP, or dependence studies published. Assessment inferred from DAT blocking activity and class-level cathinone reinforcement data (Watterson & Olive 2014). Lower DAT potency than mephedrone/MDPV predicts moderate rather than high dependence liability. | ||
ReasoningReasoningNo butylone-specific self-administration, CPP, or dependence studies published. Assessment inferred from DAT blocking activity and class-level cathinone reinforcement data (Watterson & Olive 2014). Lower DAT potency than mephedrone/MDPV predicts moderate rather than high dependence liability. Evidence basis: structural_analogy | |||
Withdrawal Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Severity | mild | mild | low |
| Symptoms | fatigue, depressed mood, anhedonia, hypersomnia, increased appetite | fatigue, depressed mood, anhedonia, hypersomnia, increased appetite | low |
| Fatal | No | No | low |
| Medical Supervision | Not required | Not required | low |
| Editorial | No butylone-specific withdrawal data. Inferred from stimulant/cathinone class withdrawal profile. Serotonergic component may add dysphoria similar to MDMA 'comedown.' | ||
ReasoningReasoningNo butylone-specific withdrawal data. Inferred from stimulant/cathinone class withdrawal profile. Serotonergic component may add dysphoria similar to MDMA 'comedown.' Evidence basis: structural_analogy | |||
Tolerance Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Buildup | moderate | moderate | low |
| Half-life | 5 days | 5 days | low |
| Full Reset | 10 days | 10 days | low |
| Cross-tolerances | methylone, mephedrone, MDMA, amphetamine, cocaine | methylone, mephedrone, MDMA, amphetamine, cocaine | low |
| Editorial | Tolerance half-life (5 days) and full reset (1.5 weeks) from existing database values (community-derived). Cross-tolerances inferred from shared DAT/SERT mechanisms. No published butylone tolerance data exist. | ||
ReasoningReasoningTolerance half-life (5 days) and full reset (1.5 weeks) from existing database values (community-derived). Cross-tolerances inferred from shared DAT/SERT mechanisms. No published butylone tolerance data exist. Evidence basis: community_consensus_small | |||
Effects & Profile
Contraindications
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| cardiovascular long QT syndrometrace | absolute | absolute | medium |
| Editorial | Class-level cathinone cardiovascular toxicity established (Prosser & Nelson 2011; Luethi & Liechti 2020). No butylone-specific cardiac data but mechanism clearly contraindicates. | ||
ReasoningReasoningClass-level cathinone cardiovascular toxicity established (Prosser & Nelson 2011; Luethi & Liechti 2020). No butylone-specific cardiac data but mechanism clearly contraindicates. | |||
| cardiovascular structural heart diseasetrace | relative | relative | medium |
| Editorial | Tachycardia >150 bpm documented in fatal case (Warrick 2012). Class-level cathinone cardiovascular toxicity well-established. | ||
ReasoningReasoningTachycardia >150 bpm documented in fatal case (Warrick 2012). Class-level cathinone cardiovascular toxicity well-established. | |||
| psychiatric psychotic disorderstrace | absolute | absolute | medium |
| Editorial | Class-level evidence that dopaminergic stimulants precipitate psychosis. Butylone's DAT blocking mechanism provides clear pharmacological basis. | ||
ReasoningReasoningClass-level evidence that dopaminergic stimulants precipitate psychosis. Butylone's DAT blocking mechanism provides clear pharmacological basis. | |||
| psychiatric bipolar disordertrace | relative | relative | low |
| Editorial | Class-level evidence from stimulant and entactogen literature. No butylone-specific case data. | ||
ReasoningReasoningClass-level evidence from stimulant and entactogen literature. No butylone-specific case data. | |||
| hepatic hepatic impairmenttrace | relative | relative | medium |
| Editorial | In vitro demonstration that CYP450 metabolism produces toxic butylone metabolites (Roque Bravo 2021). Hepatic impairment alters CYP activity unpredictably. | ||
ReasoningReasoningIn vitro demonstration that CYP450 metabolism produces toxic butylone metabolites (Roque Bravo 2021). Hepatic impairment alters CYP activity unpredictably. | |||
| other concurrent serotonergic medicationtrace | absolute | absolute | high |
| Editorial | Direct evidence of lethal serotonin syndrome from combined serotonergic cathinones (Warrick 2012). Mechanism is additive serotonin elevation exceeding toxic threshold. | ||
ReasoningReasoningDirect evidence of lethal serotonin syndrome from combined serotonergic cathinones (Warrick 2012). Mechanism is additive serotonin elevation exceeding toxic threshold. | |||
| neurological epilepsytrace | relative | relative | low |
| Editorial | Class-level cathinone/stimulant seizure risk. No butylone-specific seizure data but pharmacological mechanism applies. | ||
ReasoningReasoningClass-level cathinone/stimulant seizure risk. No butylone-specific seizure data but pharmacological mechanism applies. | |||
| pregnancy breastfeeding pregnancy and breastfeedingtrace | absolute | absolute | low |
| Editorial | No data exist; absolute contraindication based on sympathomimetic mechanism and precautionary principle applied to pregnancy. | ||
ReasoningReasoningNo data exist; absolute contraindication based on sympathomimetic mechanism and precautionary principle applied to pregnancy. | |||
Timeline Phases
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 900–3600 sec(i=0.05) | 900–3600 sec(i=0.05) | low |
| Editorial | No published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. | ||
ReasoningReasoningNo published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. Evidence basis: community_consensus_small | |||
| Come uptrace | 900–1800 sec(i=0.30) | 900–1800 sec(i=0.30) | low |
| Editorial | No published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. | ||
ReasoningReasoningNo published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. Evidence basis: community_consensus_small | |||
| Peaktrace | 3600–5400 sec(i=1.00) | 3600–5400 sec(i=1.00) | low |
| Editorial | No published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. | ||
ReasoningReasoningNo published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. Evidence basis: community_consensus_small | |||
| Plateautrace | 2700–5400 sec(i=0.50) | 2700–5400 sec(i=0.50) | low |
| Editorial | No published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. | ||
ReasoningReasoningNo published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. Evidence basis: community_consensus_small | |||
| Resolutiontrace | 1800–3600 sec(i=0.20) | 1800–3600 sec(i=0.20) | low |
| Editorial | No published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. | ||
ReasoningReasoningNo published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. Evidence basis: community_consensus_small | |||
| Afterglowtrace | 7200–14400 sec(i=0.05) | 7200–14400 sec(i=0.05) | low |
| Editorial | No published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. | ||
ReasoningReasoningNo published human pharmacokinetic data for butylone. Timeline inferred from community-reported duration (total 3-5h oral, onset 15-60 min) and comparison with methylone's known profile. All phase durations are estimates requiring editorial verification. Evidence basis: community_consensus_small | |||
Dose Tier Summaries
At threshold doses, effects are barely perceptible: a faint lift in mood, subtle increase in sociability, and mild physical energy that could be mistaken for caffeine or a good night's sleep. No overt stimulation or entactogenic warmth is present — awareness of altered state comes only in retrospect or through careful self-observation. Physically, slight pupil dilation and a marginal increase in heart rate may occur. Appetite suppression is minimal. Sleep is unlikely to be significantly disrupted if effects are allowed to fully resolve.
No published human dose-response data for butylone. Threshold effects inferred from methylone class analogy and community reports. No controlled studies define the threshold dose.
ReasoningReasoning
No published human dose-response data for butylone. Threshold effects inferred from methylone class analogy and community reports. No controlled studies define the threshold dose.
Evidence basis: structural_analogy
At light doses, the hybrid stimulant-entactogen character begins to emerge. Mild euphoria, increased talkativeness, and a subtle sense of emotional openness become noticeable. Mental stimulation manifests as thought acceleration and enhanced engagement with conversation or music. Physical effects include moderate pupil dilation, slight jaw tension, increased heart rate, and mild appetite suppression. Body temperature may rise slightly. The experience is manageable and allows normal social functioning, though subtle enough that effects may disappoint users expecting MDMA-like intensity. Sleep will be difficult for 2-3 hours after effects subside.
Inferred from methylone light-dose profile and community reports describing butylone as 'similar to but milder than MDMA.' No controlled human studies.
ReasoningReasoning
Inferred from methylone light-dose profile and community reports describing butylone as 'similar to but milder than MDMA.' No controlled human studies.
Evidence basis: structural_analogy
At common doses, butylone's dual pharmacology becomes fully apparent. Stimulation is prominent — increased energy, thought acceleration, enhanced motivation — while entactogenic effects manifest as empathy enhancement, emotional warmth, music enhancement, and increased tactile pleasure. Social inhibitions decrease and conversation flows freely. Physically, moderate tachycardia, pupil dilation, jaw clenching (bruxism), and diaphoresis are typical. Body temperature elevation occurs; dehydration risk increases with physical activity. Peripheral vasoconstriction may produce cool extremities. Functional impairment is moderate. Sleep is impossible during effects and difficult for 1-2 hours afterward. Total commitment is approximately 4-6 hours including residual stimulation.
Inferred from methylone common-dose profile and butylone's established pharmacology (DAT blocker + SERT substrate). No controlled human data; community reports describe 'milder MDMA-like' effects.
ReasoningReasoning
Inferred from methylone common-dose profile and butylone's established pharmacology (DAT blocker + SERT substrate). No controlled human data; community reports describe 'milder MDMA-like' effects.
Evidence basis: structural_analogy
At strong doses, stimulant effects dominate: pronounced euphoria, significant psychomotor activation, rapid thought patterns, and intense sociability. Entactogenic warmth remains present but may be overshadowed by stimulant drive. Some users report mild visual enhancement (color brightening, increased pattern recognition) at this range. Cardiovascular strain becomes significant — marked tachycardia, hypertension, profuse sweating, and meaningful hyperthermia risk. Bruxism intensifies. Risk of anxiety, agitation, or paranoia increases, particularly in unfamiliar settings. The serotonergic load at this range raises concern for incipient serotonergic toxicity signs. Sleep is impossible for the duration plus several hours. Cognitive impairment is notable — decision-making and risk assessment are compromised.
Inferred from class-level cathinone dose-response and methylone strong-dose effects. No controlled butylone data. Cardiovascular and serotonergic risks extrapolated from case report presentations.
ReasoningReasoning
Inferred from class-level cathinone dose-response and methylone strong-dose effects. No controlled butylone data. Cardiovascular and serotonergic risks extrapolated from case report presentations.
Evidence basis: structural_analogy
At heavy doses, butylone poses serious acute toxicity risk. The stimulant-entactogen balance shifts entirely toward sympathomimetic crisis: severe tachycardia, dangerous hyperthermia, profuse diaphoresis, and risk of serotonin syndrome. Psychological effects may include severe agitation, confusion, paranoia, or panic. At the extreme end of this range, loss of consciousness is possible. The only published human outcome data at unambiguously heavy doses is a fatality (20 mg/L blood concentration from intentional overdose). Serotonin syndrome presenting as hyperthermia >41°C, clonus, and multi-organ failure has been documented with combined cathinone ingestion in this range. This dose range carries risk of death. Emergency medical attention is required for any presentation involving hyperthermia, seizures, or loss of consciousness.
Fatal case reports (Rojek 2012 at 20 mg/L; Warrick 2012 with combined cathinones) establish that heavy doses produce lethal outcomes. No controlled dose-response data define the boundary between strong and heavy.
ReasoningReasoning
Fatal case reports (Rojek 2012 at 20 mg/L; Warrick 2012 with combined cathinones) establish that heavy doses produce lethal outcomes. No controlled dose-response data define the boundary between strong and heavy.
Evidence basis: published_case_series
History
backfill Jun 4, 2026
Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.
Sources
- [1]moderateThe synthetic cathinones, butylone and pentylone, are stimulants that act as dopamine transporter blockers but 5-HT transporter substrates.Saha K, Li Y, Holy M, Lehner KR, Bukhari MO, Partilla JS, Sandtner W, Sitte HH, Baumann MH · 2019 · Psychopharmacology
- [2]moderatePharmacological characterization of designer cathinones in vitroSimmler LD, Buser TA, Donzelli M, et al. · 2012 · British Journal of Pharmacologydoi.org/10.1111/j.1476-5381.2012.02145.x13 claims checked7 verified2 partial4 inconclusive
- [3]weakSchedules of Controlled Substances: Placement of 10 Synthetic Cathinones Into Schedule I (Permanent)Drug Enforcement Administration · 2017linkno claims checked
- [4]moderateSubstituted methcathinones differ in transporter and receptor interactionsEshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A · 2013 · Biochemical Pharmacology
- [5]weakLethal serotonin syndrome after methylone and butylone ingestion.Warrick BJ, Wilson J, Hedge M, Freeman S, Leonard K, Aaron C · 2012 · Journal of Medical Toxicology
- [6]weakLegal highs--toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-MBDB administration.Rojek S, Kłys M, Strona M, Maciów M, Kula K · 2012 · Forensic Science International
- [7]moderateThe designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissueBaumann MH, Ayestas MA, Partilla JS, et al. · 2012 · Neuropsychopharmacology
- [8]moderateComparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methyloneLopez-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E, Camarasa J · 2012 · British Journal of Pharmacology
- [9]weak
- [10]weak
- [11]moderateDARK Classics in Chemical Neuroscience: Cathinone-Derived PsychostimulantsSimmons SJ, Leyrer-Jackson JM, Oliver CF, Hicks C, Muschamp JW, Rawls SM, Olive MF · 2018 · ACS Chemical Neuroscience
- [12]moderateFrom street to lab: in vitro hepatotoxicity of buphedrone, butylone and 3,4-DMMC.Roque Bravo R, Carmo H, Valente MJ, Silva JP, Carvalho F, Bastos ML, Dias da Silva D · 2021 · Archives of Toxicology
- [13]moderateTesting for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine.Uralets V, Rana S, Morgan S, Ross W · 2014 · Journal of Analytical Toxicology
- [14]moderateSynthetic Cathinones Induce Cell Death in Dopaminergic SH-SY5Y Cells via Stimulating Mitochondrial Dysfunction.Leong HS, Philp M, Simone M, Witting PK, Fu S · 2020 · International Journal of Molecular Sciences
- [15]moderateAnalysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicologyMarinetti LJ, Antonides HM · 2013 · Journal of Analytical Toxicology
- [16]moderateSynthetic cathinones related fatalities: an updateZaami S, Giorgetti R, Pichini S, et al. · 2018 · European Review for Medical and Pharmacological Sciences
- [17]moderateA 3-year review of new psychoactive substances in caseworkElliott S, Evans J · 2014 · Forensic Science International
- [18]moderateEmerging drugs of abuse: current perspectives on substituted cathinonesDebruyne D, Loilier M, Cesbron A, Le Boisselier R, Bourgine J · 2014 · Substance Abuse and Rehabilitation
- [19]moderateThe Toxicology of Bath Salts: A Review of Synthetic CathinonesProsser J, Nelson L · 2011 · Journal of Medical Toxicologydoi.org/10.1007/s13181-011-0193-z1 claim checked1 inconclusive
- [20]strongDesigner drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · 2020 · Archives of Toxicology
- [21]moderatePatterns of Use, Acute Subjective Experiences, and Motivations for Using Synthetic Cathinones in Recreational UsersAshrafioun L, Bonadio FA, Baik KD, et al. · 2016 · Journal of psychoactive drugspubmed 276815831 claim checked1 inconclusive
- [22]moderateSynthetic Cathinones and Their Rewarding and Reinforcing Effects in Rodents.Watterson LR, Olive MF · 2014 · Advances in Neuroscience
Claim Verification
Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.
summary5 claims4verified1partial
partialWith an estimated total duration of 3–5 hours oral and moderate potency relative to methylone and mdma, butylone occupies a middle position in the methylenedioxy cathinone series — shorter-acting than MDMA but pharmacologically less potent than methylone at monoamine transporters.[4]model confidence 82%
The abstract confirms butylone is a 'lower affinity uptake inhibitor' relative to methylone/mephedrone, supporting the potency comparison. However, the specific duration claim ('3–5 hours oral') is entirely absent from this abstract, which only covers transporter binding and receptor data. Duration is a specific factual assertion not addressed here.
Butylone classified as lower affinity uptake inhibitor at DAT, SERT, NET. Mephedrone, methylone: transporter substrates that induce release.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedButylone exhibits a dual transporter mechanism: it functions as a dopamine transporter (DAT) blocker (uptake inhibitor) while simultaneously acting as a serotonin transporter (SERT) substrate (releaser)[1]model confidence 99%
Abstract directly states: 'Butylone acts as a DAT blocker and 5-HT transporter substrate.' This is a verbatim match to the claim.
Butylone acts as a DAT blocker and 5-HT transporter substrate, characterizing its mixed stimulant/entactogen profile.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedThis mechanistic split — cocaine-like at DAT, MDMA-like at SERT — produces a hybrid stimulant-entactogen phenomenology: increased energy and euphoria from dopaminergic reuptake inhibition, with empathogenic warmth and prosocial effects mediated by serotonin release[2]model confidence 92%
Abstract states butylone acts as 'non-selective monoamine uptake inhibitor similar to cocaine' and 'induces 5-HT release similar to MDMA.' The phenomenological inference (hybrid stimulant-entactogen) is a reasonable and standard interpretation of this dual mechanism.
Butylone acts as a non-selective monoamine uptake inhibitor similar to cocaine, and also induces 5-HT release similar to MDMA.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedTwo human fatalities are documented: one from combined methylone-butylone serotonin syndrome (blood concentration unreported for butylone alone), and one isolated butylone suicide at a blood concentration of 20 mg/L[5]model confidence 88%
Abstract confirms the combined methylone-butylone serotonin syndrome fatality case. This citation supports the first of the two fatalities described in the compound claim. No blood concentrations are reported in the abstract, consistent with the claim's parenthetical note.
Case report of lethal serotonin syndrome after combined methylone and butylone ingestion.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedTwo human fatalities are documented: one from combined methylone-butylone serotonin syndrome (blood concentration unreported for butylone alone), and one isolated butylone suicide at a blood concentration of 20 mg/L[6]model confidence 97%
Abstract directly confirms the isolated butylone suicide with blood concentration of 20 mg/L, supporting the second fatality in the compound claim.
Case report: 21-year-old male suicide who ingested bk-MBDB (butylone). Blood concentration 20 mg/L; liver concentration 33 mg/kg. Death within ~4 hours of hospitalization.
checked by claude-sonnet-4-6 · May 3, 2026
history5 claims4verified1inconclusive
inconclusiveThe first reported human death involving butylone was documented by Warrick et al. (2012): a 24-year-old woman died of serotonin syndrome after ingesting capsules containing methylone and butylone sold as "Ecstasy" at a concert[5]model confidence 70%
The abstract confirms a case report of lethal serotonin syndrome from combined methylone and butylone ingestion. However, the specific details — patient age (24-year-old), sex (woman), setting (concert), product description (Ecstasy capsules), and priority claim ('first reported') — are not verifiable from the abstract and would require the full text.
Case report of lethal serotonin syndrome after combined methylone and butylone ingestion. Designer phenethylamines marketed as legal highs with similar pharmacodynamics to scheduled drugs.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedA second fatality — an isolated butylone suicide in Poland — was reported by Rojek et al. the same year.[6]model confidence 88%
Abstract confirms a case report of isolated butylone (bk-MBDB) suicide with fatal outcome. The country (Poland) and author name (Rojek) are not in the abstract but are consistent with the scope note and the core claim — an isolated butylone suicide — is directly confirmed.
Case report: 21-year-old male suicide who ingested bk-MBDB (butylone). Blood concentration 20 mg/L; liver concentration 33 mg/kg. Death within ~4 hours of hospitalization.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedBaumann et al. (2012), in a study co-authored by Alexander Shulgin, characterized the broader class of methylenedioxy cathinones (mephedrone, methylone) as monoamine transporter substrates analogous to MDMA, providing the pharmacological framework within which butylone was subsequently studied[7]model confidence 90%
Abstract confirms methylone and mephedrone are 'nonselective substrates for monoamine transporters' and increase extracellular DA and 5-HT similarly to MDMA. The Shulgin co-authorship is in the scope note. The pharmacological framework claim is directly supported.
Methylone and mephedrone are nonselective substrates for monoamine transporters. IV administration increases extracellular DA and 5-HT in rat NAc.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedThe first dedicated pharmacology papers appeared in 2012: López-Arnau et al. published comparative neuropharmacology data, and Simmler et al. characterized it as a non-selective uptake inhibitor with serotonin-releasing properties.[8]model confidence 88%
Abstract confirms the type of data published (comparative neuropharmacology: locomotor effects, transporter inhibition, 5-HT2A affinities). The 2012 date cannot be verified from the abstract alone but the paper type and content match the claim.
Butylone (5-25 mg/kg) caused hyperlocomotion in mice; inhibited 5-HT and dopamine uptake; affinities for 5-HT2A receptors similar to MDMA.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedThe first dedicated pharmacology papers appeared in 2012: López-Arnau et al. published comparative neuropharmacology data, and Simmler et al. characterized it as a non-selective uptake inhibitor with serotonin-releasing properties.[2]model confidence 93%
Abstract directly confirms Simmler et al. classified butylone as 'non-selective monoamine uptake inhibitor' with '5-HT release similar to MDMA,' matching the characterization described in the claim.
Butylone acts as a non-selective monoamine uptake inhibitor similar to cocaine, and also induces 5-HT release similar to MDMA.
checked by claude-sonnet-4-6 · May 3, 2026
chemistry2 claims2inconclusive
inconclusiveThe β-keto group (carbonyl at the β-position) distinguishes cathinones from their corresponding amphetamine analogues and reduces blood-brain barrier penetration relative to the non-keto parent compounds, though butylone retains high BBB permeability in vitro.[2]model confidence 68%
Abstract confirms high BBB permeability for butylone in vitro. However, the specific claim that β-keto generally reduces BBB penetration relative to non-keto parent compounds (the comparison) is not addressed in the abstract — this would be a discussion or introduction point in the full paper.
High blood-brain barrier permeability in vitro model.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveFor comparison, the structurally related cathinone mephedrone demonstrates significant stereoselective differences in reinforcing properties between its enantiomers, suggesting that butylone enantiomers may similarly differ in pharmacological profile — a research gap that remains unaddressed.[11]model confidence 55%
Abstract is a general historical review covering mechanisms of action and behavioral effects. The specific claim about mephedrone enantiomer stereoselective differences in reinforcing properties is not mentioned in the abstract. This data would need to be in the full review text.
Historical review: synthetic cathinone history, DEA Schedule I emergency scheduling 2012, mechanisms of action, behavioral effects in animals, class overview.
checked by claude-sonnet-4-6 · May 3, 2026
pharmacology12 claims11verified1partial
verifiedAt the dopamine transporter, butylone functions as an uptake inhibitor (blocker) rather than a releasing substrate, placing it in the cocaine-like mechanistic category at this site[1]model confidence 99%
Abstract directly states 'Butylone acts as a DAT blocker,' confirming uptake inhibitor (not substrate/releaser) mechanism at DAT.
Butylone acts as a DAT blocker and 5-HT transporter substrate, characterizing its mixed stimulant/entactogen profile.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedThis is corroborated by Eshleman et al. (2013), who describe butylone as a "lower affinity uptake inhibitor" at human recombinant DAT compared to mephedrone and methylone.[4]model confidence 95%
Abstract explicitly uses the phrase 'lower affinity uptake inhibitor at DAT' for butylone, while classifying mephedrone and methylone as substrate/releasers (a distinct, higher-efficacy mechanism). The comparison is well-supported.
Butylone classified as lower affinity uptake inhibitor at DAT, SERT, NET. MDPV and naphyrone: pure uptake inhibitors. Mephedrone, methylone: transporter substrates that induce release.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedAt the serotonin transporter, butylone acts as a substrate — it is transported into the presynaptic terminal and triggers non-exocytotic serotonin release via transporter reversal, mechanistically analogous to MDMA[1]model confidence 90%
Abstract confirms butylone acts as a '5-HT transporter substrate.' The mechanistic detail (non-exocytotic release via transporter reversal) is standard pharmacological inference from 'substrate' classification — not contradicted and well within what the abstract supports.
Butylone acts as a DAT blocker and 5-HT transporter substrate, characterizing its mixed stimulant/entactogen profile.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedSimmler et al. (2012) confirm that butylone induces 5-HT release in addition to uptake inhibition.[2]model confidence 99%
Abstract directly states butylone 'induces 5-HT release similar to MDMA' and acts as 'non-selective monoamine uptake inhibitor.' Both aspects of the claim are directly confirmed.
Butylone acts as a non-selective monoamine uptake inhibitor similar to cocaine, and also induces 5-HT release similar to MDMA.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedSimmler et al. (2012) initially classified butylone as a "non-selective monoamine uptake inhibitor similar to cocaine", while the more recent and mechanistically granular characterization by Saha et al. (2019) resolves the SERT substrate distinction[2]model confidence 95%
Abstract directly quotes the 'non-selective monoamine uptake inhibitor similar to cocaine' classification. This citation is for Simmler's classification specifically, which is confirmed verbatim.
Butylone acts as a non-selective monoamine uptake inhibitor similar to cocaine, and also induces 5-HT release similar to MDMA.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedSimmler et al. (2012) initially classified butylone as a "non-selective monoamine uptake inhibitor similar to cocaine", while the more recent and mechanistically granular characterization by Saha et al. (2019) resolves the SERT substrate distinction[1]model confidence 93%
This citation (Saha et al.) is the paper that resolves the SERT substrate distinction. The abstract directly identifies butylone as 'DAT blocker and 5-HT transporter substrate,' which is the mechanistically granular SERT substrate characterization referenced in the claim.
Butylone acts as a DAT blocker and 5-HT transporter substrate, characterizing its mixed stimulant/entactogen profile.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedUnlike mephedrone and methylone, it does not robustly release preloaded norepinephrine in superfusion assays.[4]model confidence 88%
Abstract classifies butylone as a 'lower affinity uptake inhibitor at NET' while mephedrone and methylone are 'transporter substrates that induce release.' This directly implies butylone lacks the robust norepinephrine-releasing activity of mephedrone/methylone. The 'superfusion assays' methodological detail is not in the abstract but is consistent with the transporter substrate characterization paradigm.
Butylone classified as lower affinity uptake inhibitor at DAT, SERT, NET. Mephedrone, methylone: transporter substrates that induce release.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedLópez-Arnau et al. (2012) demonstrated dose-dependent hyperlocomotion in mice at 5–25 mg/kg i.p., blocked by both ketanserin (5-HT₂A antagonist) and haloperidol (D₂ antagonist)[8]model confidence 98%
Abstract directly confirms: butylone at 5–25 mg/kg caused hyperlocomotion in mice, and hyperlocomotion was prevented with both ketanserin and haloperidol.
Butylone (5-25 mg/kg) caused hyperlocomotion in mice; inhibited 5-HT and dopamine uptake; affinities for 5-HT2A receptors similar to MDMA. Hyperlocomotion prevented with ketanserin or haloperidol.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedMicrodialysis data exist for the related cathinones methylone and mephedrone, but direct measurement of butylone's effects on extracellular monoamine concentrations in vivo remains a gap.[7]model confidence 90%
Abstract confirms IV administration of methylone and mephedrone increases extracellular DA and 5-HT in rat nucleus accumbens (in vivo microdialysis data). The claim uses this paper to establish that such data exist for methylone/mephedrone — confirmed — while the gap for butylone is a reasonable inference from the paper not including butylone.
Methylone and mephedrone are nonselective substrates for monoamine transporters. IV administration increases extracellular DA and 5-HT in rat NAc.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedUralets et al. (2014) conducted the largest human urinary excretion study for synthetic cathinones, finding that methylenedioxy-substituted cathinones (including butylone) undergo carbonyl reduction to a lesser extent than non-methylenedioxy cathinones[13]model confidence 90%
Abstract directly confirms the key finding: methylenedioxy-substituted cathinones including butylone metabolize via carbonyl reduction to a lesser extent. The 'largest' superlative cannot be verified from the abstract alone but is a minor claim relative to the core metabolic finding, which is directly supported.
SC with methylenedioxy attachment to aromatic ring (including butylone) metabolize by carbonyl reduction to lesser extent; best detected as parent drug in free urine fraction.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedRoque Bravo et al. (2021) confirmed CYP450 involvement in butylone metabolism using selective inhibitors in primary rat hepatocytes, but did not identify the specific CYP isoforms responsible[12]model confidence 88%
Abstract confirms CYP450 involvement via inhibition experiments in primary rat hepatocytes. The claim that specific isoforms were not identified is consistent with the abstract, which mentions CYP450 inhibition increased toxicity without naming specific isoforms.
CYP450 inhibition increased butylone toxicity (metabolic activation produces toxic metabolites).
checked by claude-sonnet-4-6 · May 3, 2026
partialThe moderate LogP (1.34) and confirmed high BBB permeability are consistent with rapid CNS penetration.[2]model confidence 80%
Abstract confirms high BBB permeability in vitro, supporting that part of the claim. However, the specific LogP value of 1.34 is not present in the abstract and cannot be verified from it. This is a specific quantitative assertion unconfirmed by the provided abstract.
High blood-brain barrier permeability in vitro model.
checked by claude-sonnet-4-6 · May 3, 2026
receptor pharmacology8 claims5verified3inconclusive
verifiedButylone's affinity at all three monoamine transporters (DAT, SERT, NET) is lower than that of methylone and mephedrone[4]model confidence 93%
Abstract explicitly classifies butylone as 'lower affinity uptake inhibitor at DAT, SERT, NET' while mephedrone and methylone are higher-efficacy substrate releasers. This directly supports the claim of lower affinity relative to those two compounds.
Butylone classified as lower affinity uptake inhibitor at DAT, SERT, NET. Mephedrone, methylone: transporter substrates that induce release.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedIts DAT/SERT selectivity ratio places it between methylone (more SERT-selective) and MDPV (highly DAT-selective), in a roughly non-selective range with preferential SERT substrate activity versus DAT blocking activity.[2]model confidence 83%
Abstract classifies butylone as 'non-selective monoamine uptake inhibitor,' consistent with the claim of roughly non-selective positioning. The SERT substrate activity (vs. DAT blocking) is consistent with Simmler's description of 5-HT release. The comparisons to methylone and MDPV are reasonable inferences not contradicted by the abstract.
Butylone acts as a non-selective monoamine uptake inhibitor similar to cocaine, and also induces 5-HT release similar to MDMA.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveSpecific Ki or IC₅₀ values for butylone at DAT, SERT, and NET are contained in Simmler et al. (2012) and Saha et al. (2019), but full numeric tables were not accessible via open-access retrieval[2]model confidence 65%
Abstract confirms Simmler et al. characterizes butylone at monoamine transporters but does not provide specific Ki or IC50 numeric values. The claim asserts these values are in the full paper (not accessible), which is consistent with the abstract's limited detail but cannot be confirmed from it.
Butylone acts as a non-selective monoamine uptake inhibitor similar to cocaine, and also induces 5-HT release similar to MDMA.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveSpecific Ki or IC₅₀ values for butylone at DAT, SERT, and NET are contained in Simmler et al. (2012) and Saha et al. (2019), but full numeric tables were not accessible via open-access retrieval[1]model confidence 65%
Abstract confirms Saha et al. characterizes butylone's transporter profile (DAT blocker, SERT substrate) but provides no specific numeric Ki or IC50 values. The claim that such values exist in the full text is plausible but cannot be verified from the abstract.
Butylone acts as a DAT blocker and 5-HT transporter substrate, characterizing its mixed stimulant/entactogen profile.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedEshleman et al. (2013) characterized butylone's activity at multiple non-transporter targets using human recombinant receptor systems:[4]model confidence 95%
Abstract confirms Eshleman et al. characterized butylone at hVMAT2, 5-HT1A, and 5-HT2A — multiple non-transporter receptor targets using human recombinant systems.
Butylone had low potency at hVMAT2, weak 5-HT1A partial agonism, 5-HT2A antagonism.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedThe 5-HT₂A finding is notable: López-Arnau et al. (2012) demonstrated that ketanserin (5-HT₂A antagonist) blocks butylone's hyperlocomotor effects in vivo, suggesting functional 5-HT₂A engagement despite the in vitro antagonist classification[8]model confidence 95%
Abstract directly confirms both relevant data points: affinities for 5-HT2A receptors similar to MDMA, and hyperlocomotion prevented with ketanserin. This confirms both the receptor affinity and the behavioral blockade.
Affinities for 5-HT2A receptors similar to MDMA. Hyperlocomotion prevented with ketanserin or haloperidol.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveSimmler et al. (2012) note that TAAR1 activity is a property of non-β-keto amphetamines but is absent in cathinone derivatives[2]model confidence 60%
TAAR1 is not mentioned in the abstract at all. This claim about TAAR1 absence in cathinone derivatives may be in the full text or supplementary data of Simmler et al., but cannot be confirmed from the abstract.
Butylone acts as a non-selective monoamine uptake inhibitor similar to cocaine, and also induces 5-HT release similar to MDMA. High blood-brain barrier permeability in vitro model.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedSimmler et al. (2012) report high BBB permeability for butylone in an in vitro model, consistent with its established CNS psychoactivity despite the β-keto group's general reduction of lipophilicity relative to non-keto analogues.[2]model confidence 97%
Abstract directly states 'High blood-brain barrier permeability in vitro model' — confirming the key finding. The mechanistic rationale about β-keto and lipophilicity is contextual interpretation not contradicted by the abstract.
High blood-brain barrier permeability in vitro model.
checked by claude-sonnet-4-6 · May 3, 2026
neuroscience4 claims4verified
verifiedClass-level evidence from synthetic cathinone self-administration studies demonstrates that DAT-active cathinones support operant responding in rodents, with reinforcing efficacy proportional to DAT potency[22]model confidence 90%
Abstract confirms rodent IV self-administration and reinforcing efficacy rank order: MDPV (highly DAT-selective, pure inhibitor) >= methamphetamine > methylone (lower DAT potency), consistent with reinforcing efficacy being proportional to DAT potency.
Rodents self-administer MDPV and methylone intravenously in patterns similar to methamphetamine. Rank order of reinforcing efficacy: MDPV >= methamphetamine > methylone.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedButylone's relatively lower DAT affinity compared to MDPV or mephedrone predicts moderate, not extreme, reinforcing potential.[4]model confidence 88%
Abstract confirms butylone has 'lower affinity' at DAT compared to pure uptake inhibitors like MDPV (which are 'pure uptake inhibitors'). The inference that lower DAT affinity predicts moderate reinforcing potential is a reasonable pharmacological prediction.
Butylone classified as lower affinity uptake inhibitor at DAT, SERT, NET. MDPV and naphyrone: pure uptake inhibitors.
checked by claude-sonnet-4-6 · May 3, 2026
verified5-HT₂A activation (indirect, via released 5-HT) — confirmed behaviorally by ketanserin blockade of butylone-induced hyperlocomotion[8]model confidence 95%
Abstract directly confirms hyperlocomotion is prevented by ketanserin (5-HT2A antagonist), confirming 5-HT2A involvement in butylone's behavioral effects.
Hyperlocomotion prevented with ketanserin or haloperidol.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedLeong et al. (2020) demonstrated that butylone produces dose-dependent neurotoxicity in differentiated SH-SY5Y (human dopaminergic neuronal) cells[14]model confidence 92%
Abstract confirms butylone neurotoxicity in SH-SY5Y cells with dose-dependent effects (ROS, mitochondrial bioenergetics, Ca2+, caspase 3/7). Author name (Leong) and year (2020) are not in abstract but the core finding matches.
Butylone neurotoxicity in SH-SY5Y: dose-dependent ROS, decreased mitochondrial bioenergetics, Ca2+ increase, caspase 3/7 activation.
checked by claude-sonnet-4-6 · May 3, 2026
pharmacokinetic detail6 claims3verified1partial2inconclusive
partialThe LogP of 1.34 and confirmed high BBB permeability in vitro predict rapid absorption and CNS penetration[2]model confidence 80%
Abstract confirms high BBB permeability in vitro, supporting CNS penetration. The specific LogP value of 1.34 is not in the abstract and cannot be verified from it. This is the same issue as Pair 19.
High blood-brain barrier permeability in vitro model.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedUralets et al. (2014) established that butylone, as a methylenedioxy-substituted cathinone, undergoes less carbonyl reduction than non-methylenedioxy cathinones[13]model confidence 97%
Abstract directly confirms: methylenedioxy-substituted cathinones including butylone 'metabolize by carbonyl reduction to lesser extent' — verbatim confirmation of the claim.
SC with methylenedioxy attachment to aromatic ring (including butylone) metabolize by carbonyl reduction to lesser extent; best detected as parent drug in free urine fraction.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedRoque Bravo et al. (2021) demonstrated CYP450-dependent metabolic activation — not detoxification — in primary rat hepatocytes[12]model confidence 97%
Abstract directly states 'CYP450 inhibition increased butylone toxicity (metabolic activation produces toxic metabolites)' — confirming CYP450-dependent metabolic activation (not detoxification) in primary rat hepatocytes.
CYP450 inhibition increased butylone toxicity (metabolic activation produces toxic metabolites).
checked by claude-sonnet-4-6 · May 3, 2026
verifiedThese predictions derive from in vitro rat hepatocyte data and have not been confirmed in human clinical settings.[12]model confidence 90%
Abstract specifies 'primary rat hepatocytes' as the experimental model, confirming the in vitro rat hepatocyte data context. The absence of human data is consistent with this being the only study cited and no human clinical confirmation is stated or implied.
Hepatotoxicity EC50 1.21 mM for butylone in primary rat hepatocytes.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveSpecific LC-MS/MS or GC-MS methods are required for identification[15]model confidence 60%
Abstract mentions 'method screens for butylone among others' but does not specify LC-MS/MS or GC-MS as the required analytical method. This methodological detail would be in the methods section of the full paper.
43 forensic cases: method screens for butylone among others.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveSpecific LC-MS/MS or GC-MS methods are required for identification[13]model confidence 60%
Abstract confirms butylone detection in human urine and notes best detection as parent drug in free urine fraction, but does not specify LC-MS/MS or GC-MS as required methods. The analytical method details would be in the full paper.
Butylone detected in human urine specimens. SC with methylenedioxy attachment... best detected as parent drug in free urine fraction.
checked by claude-sonnet-4-6 · May 3, 2026
effects overview1 claim1verified
verifiedCompared to methylone, the experience is similar in character but lower in ceiling intensity, reflecting butylone's reduced affinity at all three monoamine transporters.[4]model confidence 88%
Abstract confirms butylone has lower affinity at all three monoamine transporters (DAT, SERT, NET) than methylone/mephedrone. The inference that lower transporter affinity corresponds to lower ceiling intensity is a standard pharmacological interpretation not contradicted by the abstract.
Butylone classified as lower affinity uptake inhibitor at DAT, SERT, NET. Mephedrone, methylone: transporter substrates that induce release.
checked by claude-sonnet-4-6 · May 3, 2026
safety16 claims6verified1partial8inconclusive1not supported
inconclusiveClass-level acute toxicity from cathinones includes tachycardia, hypertension, hyperthermia, and in severe cases rhabdomyolysis, metabolic acidosis, and multi-organ failure.[18]model confidence 72%
Abstract confirms tachycardia, hypertension, agitation, seizures, and hyperthermia as part of cathinone clinical presentation. However, the severe complications specifically cited — rhabdomyolysis, metabolic acidosis, multi-organ failure — are not mentioned in the abstract and would require the full text of this review to verify.
Review of substituted cathinones including clinical presentation (tachycardia, hypertension, agitation, seizures, hyperthermia) and management.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveThe Warrick case (combined methylone + butylone serotonin syndrome, death at 48h) and the Rojek case (isolated butylone intentional overdose, blood 20 mg/L, death at ~4h) constitute the complete published human acute toxicity dataset.[5]model confidence 70%
Abstract confirms the combined methylone+butylone serotonin syndrome fatal case (Warrick). The specific timing of 'death at 48h' is not in the abstract — it would be in the case report body. The 'complete dataset' assertion is also unverifiable from the abstract alone.
Case report of lethal serotonin syndrome after combined methylone and butylone ingestion.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedThe Warrick case (combined methylone + butylone serotonin syndrome, death at 48h) and the Rojek case (isolated butylone intentional overdose, blood 20 mg/L, death at ~4h) constitute the complete published human acute toxicity dataset.[6]model confidence 92%
Abstract confirms the Rojek case details: isolated butylone (bk-MBDB) suicide, blood concentration 20 mg/L, death within ~4 hours. These match the claim's characterization of the Rojek case exactly.
Case report: 21-year-old male suicide who ingested bk-MBDB (butylone). Blood concentration 20 mg/L; liver concentration 33 mg/kg. Death within ~4 hours of hospitalization.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedThe 20 mg/L postmortem blood concentration in the Rojek case is exceptionally high — most cathinone-related fatalities involve blood concentrations below 1 mg/L[16]model confidence 97%
Abstract directly states 'Fatal concentrations rarely exceed 1 mg/L in postmortem fluids,' directly supporting the claim that most cathinone fatalities are below 1 mg/L and that 20 mg/L is exceptionally high.
Fatal concentrations rarely exceed 1 mg/L in postmortem fluids.
checked by claude-sonnet-4-6 · May 3, 2026
not supportedElliott and Evans (2014) note that for cathinones generally, blood concentration does not reliably predict outcome.[17]model confidence 85%
cited source's abstract does not support this claim — flagged for editorial review
The abstract for this citation covers forensic casework demographics (41% of cathinone fatality cases were hangings, 7% of drug deaths solely involved NPS) and does not contain any statement about blood concentration not predicting outcome. This specific finding is found in citation [19] (Pair 26), not this abstract.
2010-2012 forensic casework: butylone detected in cases. 41% of cathinone fatality cases were hangings. 7% of drug deaths solely involved NPS.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedElliott and Evans (2014) note that for cathinones generally, blood concentration does not reliably predict outcome.[15]model confidence 97%
Abstract directly states 'Blood concentration does not predict outcome for fatalities or impairment,' which is a verbatim match to the claim.
Blood concentration does not predict outcome for fatalities or impairment.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveClass-level acute toxicity from cathinones includes tachycardia, hypertension, hyperthermia, and in severe cases rhabdomyolysis, metabolic acidosis, and multi-organ failure.[19]model confidence 65%
The abstract is extremely brief ('Review of synthetic cathinone toxicology, pharmacology, clinical presentation, and management. 695 citations.'). While the paper clearly covers the right topic, the abstract provides no specific detail to confirm or deny the listed severe complications.
Review of synthetic cathinone toxicology, pharmacology, clinical presentation, and management. 695 citations.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveClass-level acute toxicity from cathinones includes tachycardia, hypertension, hyperthermia, and in severe cases rhabdomyolysis, metabolic acidosis, and multi-organ failure.[20]model confidence 68%
Abstract mentions 'sympathomimetic adverse effects' for cathinones, consistent with tachycardia/hypertension, but does not specifically enumerate rhabdomyolysis, metabolic acidosis, or multi-organ failure. These severe complications may be in the full text of this comprehensive review.
Comprehensive review: stimulants including cathinones primarily interact with monoamine transporters; sympathomimetic adverse effects.
checked by claude-sonnet-4-6 · May 3, 2026
partialRoque Bravo et al. (2021) characterized butylone hepatotoxicity in three cell models:[12]model confidence 78%
Abstract confirms hepatotoxicity characterization in primary rat hepatocytes (one cell model explicitly) with EC50, CYP450 involvement, and mechanisms. However, 'three cell models' is a specific factual assertion — the abstract only mentions primary rat hepatocytes. The other two models are not named in the abstract.
Hepatotoxicity EC50 1.21 mM for butylone in primary rat hepatocytes. CYP450 inhibition increased butylone toxicity (metabolic activation produces toxic metabolites). Mitochondrial disruption, oxidative stress, apoptosis/necrosis, autophagy.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedIn vitro neurotoxicity is demonstrated in differentiated human SH-SY5Y neuroblastoma cells: dose-dependent cell death via ROS production (p < 0.0001), decreased mitochondrial bioenergetics, calcium dysregulation, and caspase 3/7-mediated apoptosis[14]model confidence 93%
Abstract directly confirms all key findings: SH-SY5Y cells, dose-dependent ROS, decreased mitochondrial bioenergetics, Ca2+ increase (calcium dysregulation), and caspase 3/7 activation. The specific p-value (p < 0.0001) and 'differentiated' cell detail are not in the abstract but are minor methodological details consistent with the study.
Butylone neurotoxicity in SH-SY5Y: dose-dependent ROS, decreased mitochondrial bioenergetics, Ca2+ increase, caspase 3/7 activation.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveClass-level evidence from synthetic cathinone user surveys documents anxiety, paranoia, agitation, and psychosis as reported adverse psychological effects[21]model confidence 65%
Abstract notes '6 negative consequences per year' and lists positive effects (energy, euphoria, etc.) but does not enumerate the specific adverse psychological effects claimed (anxiety, paranoia, agitation, psychosis). These may be in the full survey data tables in the paper.
104 recreational cathinone users: 60% used monthly, effects included increased energy, euphoria, rapid heartbeat, decreased appetite, increased sex drive. Average 6 negative consequences per year.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveThe serotonin syndrome presentation in the Warrick case included coma and agitation prior to cardiovascular collapse.[5]model confidence 65%
Abstract confirms the case involved lethal serotonin syndrome from combined methylone and butylone ingestion but provides no clinical details about specific presentation features (coma, agitation, cardiovascular collapse). These details are in the case report body, not the abstract.
Case report of lethal serotonin syndrome after combined methylone and butylone ingestion.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedClass-level evidence from animal self-administration studies demonstrates that cathinones with DAT activity support operant responding, with reinforcing efficacy proportional to DAT potency.[22]model confidence 88%
Abstract confirms rodent self-administration and rank-order reinforcing efficacy: MDPV (high DAT potency pure inhibitor) >= methamphetamine > methylone (lower DAT potency substrate). This rank order is consistent with reinforcing efficacy being proportional to DAT potency.
Rodents self-administer MDPV and methylone intravenously in patterns similar to methamphetamine. Rank order of reinforcing efficacy: MDPV >= methamphetamine > methylone.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveClass-level evidence from animal self-administration studies demonstrates that cathinones with DAT activity support operant responding, with reinforcing efficacy proportional to DAT potency.[11]model confidence 60%
Abstract describes a historical review covering mechanisms of action and behavioral effects in animals, which is the right topic. However, the abstract provides no specific data on self-administration or reinforcing efficacy proportional to DAT potency. This data may be in the full review text.
Historical review: synthetic cathinone history, DEA Schedule I emergency scheduling 2012, mechanisms of action, behavioral effects in animals, class overview.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveThe Warrick (2012) case directly documents fatal serotonin syndrome from combined methylone and butylone ingestion (~844 mg methylone + ~106 mg butylone)[5]model confidence 70%
Abstract confirms fatal serotonin syndrome from combined methylone and butylone ingestion. The specific doses (~844 mg methylone + ~106 mg butylone) are highly specific quantitative details not in the abstract — they would be in the body of the case report.
Case report of lethal serotonin syndrome after combined methylone and butylone ingestion.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedRoque Bravo et al. (2021) demonstrated that CYP450 inhibitors increase butylone hepatotoxicity in vitro[12]model confidence 98%
Abstract directly states 'CYP450 inhibition increased butylone toxicity.' This is a direct confirmation of the claim.
CYP450 inhibition increased butylone toxicity (metabolic activation produces toxic metabolites).
checked by claude-sonnet-4-6 · May 3, 2026
clinical evidence3 claims1verified2inconclusive
inconclusiveThe blood concentration of 20 mg/L is described by the authors as "extremely high"[6]model confidence 65%
Abstract confirms blood concentration of 20 mg/L in this case but does not reproduce the quoted phrase 'extremely high.' This specific quoted language would be in the body of the paper, not the abstract. The data might be in the full text.
Case report: 21-year-old male suicide who ingested bk-MBDB (butylone). Blood concentration 20 mg/L; liver concentration 33 mg/kg.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedFor context, most cathinone-related fatalities rarely exceed 1 mg/L in postmortem blood, and this case is consistent with massive intentional ingestion rather than typical recreational dosing.[16]model confidence 95%
Abstract directly states 'Fatal concentrations rarely exceed 1 mg/L in postmortem fluids.' The inference about intentional vs. recreational dosing is reasonable given 20 mg/L vs. the <1 mg/L typical range.
Fatal concentrations rarely exceed 1 mg/L in postmortem fluids.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveThis case represents the first reported human death involving butylone and the first known documented human ingestion[5]model confidence 60%
Abstract confirms a case report of lethal serotonin syndrome from combined methylone and butylone ingestion but does not establish priority ('first reported'). The claim about this being both the first death and first documented human ingestion is a specific historical assertion not verifiable from the abstract.
Case report of lethal serotonin syndrome after combined methylone and butylone ingestion.
checked by claude-sonnet-4-6 · May 3, 2026
comparative pharmacology5 claims3verified2inconclusive
inconclusiveThis table illustrates a systematic shift across the series: as α-alkyl chain length increases, the mechanism transitions from SERT substrate (releaser) to SERT blocker, and DAT selectivity increases[1]model confidence 65%
Abstract confirms butylone is a DAT blocker and SERT substrate, and mentions pentylone alongside. However, verifying a systematic mechanistic shift across the methylone→butylone→pentylone series would require data on all three compounds' SERT mechanisms, which is not fully detailed in the abstract.
Butylone and pentylone are derivatives of methylone. Butylone acts as a DAT blocker and 5-HT transporter substrate, characterizing its mixed stimulant/entactogen profile.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedThis table illustrates a systematic shift across the series: as α-alkyl chain length increases, the mechanism transitions from SERT substrate (releaser) to SERT blocker, and DAT selectivity increases[4]model confidence 82%
Abstract demonstrates part of the shift: methylone/mephedrone are substrate releasers while butylone is an uptake inhibitor. This distinction supports the claim of a mechanistic shift with chain length, at least for the methylone→butylone transition.
Butylone classified as lower affinity uptake inhibitor at DAT, SERT, NET. Mephedrone, methylone: transporter substrates that induce release.
checked by claude-sonnet-4-6 · May 3, 2026
inconclusiveTAAR1: MDMA activates TAAR1; butylone does not (β-keto group prevents TAAR1 binding)[2]model confidence 55%
TAAR1 is not mentioned in the abstract at all. This specific claim about TAAR1 and the β-keto group's role would need to be verified against the full text.
Butylone acts as a non-selective monoamine uptake inhibitor similar to cocaine, and also induces 5-HT release similar to MDMA. High blood-brain barrier permeability in vitro model.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedSimmler et al. (2012) classified butylone as pharmacologically similar to cocaine (non-selective uptake inhibitor)[2]model confidence 99%
Abstract directly states 'non-selective monoamine uptake inhibitor similar to cocaine' — verbatim confirmation.
Butylone acts as a non-selective monoamine uptake inhibitor similar to cocaine.
checked by claude-sonnet-4-6 · May 3, 2026
verifiedThe comparison is partially apt — both are monoamine uptake inhibitors — but butylone's additional SERT substrate (releasing) activity and absence of local anesthetic (sodium channel blocking) properties distinguish it mechanistically[1]model confidence 85%
Abstract confirms butylone's SERT substrate (releasing) activity, which is the primary mechanistic distinction being cited here. The sodium channel blocking absence is not addressed but also not contradicted by the abstract.
Butylone acts as a DAT blocker and 5-HT transporter substrate, characterizing its mixed stimulant/entactogen profile.
checked by claude-sonnet-4-6 · May 3, 2026
Coverage & Gaps
Research Trail
substance-article pipeline-v5 May 3, 2026
| Step | Source | Query | Results |
|---|---|---|---|
| 1database lookup | PubChem | Butylone | 1 result, 1 selected |
selection rationaleselection rationaleOnly result; confirms seed data chemical identity | |||
| 2literature search | PubMed | Butylone bk-MBDB pharmacology cathinone | 4 results, 4 selected |
selection rationaleselection rationaleAll directly relevant to butylone pharmacology, toxicology, and safety | |||
| 3literature search | OpenAlex | Butylone bk-MBDB synthetic cathinone | 10 results, 5 selected |
selection rationaleselection rationaleHigh-citation landmark papers directly relevant to butylone pharmacology, toxicity, and detection | |||
| 4document retrieval | PubMed | PMID 22160789 | 1 result, 1 selected |
selection rationaleselection rationaleCritical safety case report specifically involving butylone | |||
| 5document retrieval | PubMed | PMID 33550444 | 1 result, 1 selected |
selection rationaleselection rationaleKey hepatotoxicity and CYP450 interaction data for butylone | |||
| 6literature search | PubMed | synthetic cathinone monoamine transporter binding affinity DAT SERT NET | 1 result, 1 selected |
selection rationaleselection rationaleContains specific butylone transporter binding data | |||
| 7clinical trial search | ClinicalTrials.gov | butylone synthetic cathinone | 0 results |
selection rationaleselection rationaleConfirms absence of clinical trial activity | |||
| 8document retrieval | OpenAlex | DOI 10.1111/j.1476-5381.2012.02145.x | 1 result, 1 selected |
selection rationaleselection rationaleLandmark pharmacology paper with specific butylone data | |||
| 9literature search | PubMed | synthetic cathinone reinforcing self-administration addiction abuse potential animal | 8 results, 1 selected |
selection rationaleselection rationaleProvides class-level context for cathinone abuse liability and DEA scheduling history | |||
| 10legal status search | WebSearch | butylone bk-MBDB DEA Schedule I scheduling date | 10 results, 2 selected |
selection rationaleselection rationaleOfficial government sources for US scheduling history | |||
| 11legal status search | WebSearch/Erowid | butylone UK Misuse of Drugs Act scheduling | 10 results, 2 selected |
selection rationaleselection rationaleComprehensive multi-jurisdiction legal status | |||
| 12document retrieval | WebSearch/Wikipedia | butylone bk-MBDB synthesis history first synthesis year discovery | 10 results, 1 selected |
selection rationaleselection rationaleHistorical synthesis and market emergence data | |||
| 13literature search | PubMed | designer cathinone neurotoxicity oxidative stress mitochondria apoptosis | 1 result, 1 selected |
selection rationaleselection rationaleSpecific neurotoxicity mechanism data for butylone | |||
| 14document retrieval | PubMed Central | PMC3550225 Warrick 2012 butylone methylone serotonin syndrome | 1 result, 1 selected |
selection rationaleselection rationaleCritical primary safety data for butylone | |||
| 15legal status search | WebSearch | butylone Canada EU scheduling | 10 results |
selection rationaleselection rationaleEstablishes gap in available legal status data for Canada and EU-wide | |||
| 16web search | WebSearch | butylone physical properties melting point solubility CAS 17762-90-2 | 10 results, 1 selected |
selection rationaleselection rationalePhysical properties data | |||
| 17web search | WebSearch | Koeppe Ludwig Zeile 1967 synthesis butylone history | 10 results, 1 selected |
selection rationaleselection rationaleHistorical origin of butylone | |||
| 18cross reference | Multiple | Butylone tramadol lethal interaction | 5 results |
selection rationaleselection rationaleSafety-critical interaction flag for editorial review | |||
| 19document retrieval | PubMed | PMID 32249347 Luethi Liechti designer drugs | 1 result, 1 selected |
selection rationaleselection rationaleAuthoritative comprehensive review for class-level adverse effects applicable to butylone | |||
| 20document retrieval | PubMed | wastewater cathinone prevalence monitoring | 5 results, 0 selected |
selection rationaleselection rationaleEstablishes that butylone has low population-level prevalence compared to other synthetic cathinones | |||
| 21cross reference | Multiple | Butylone stereochemistry enantiomer data | 0 results |
selection rationaleselection rationaleEstablishes gap in stereochemistry data for butylone | |||
| 22data extraction | PubChem/Web | Butylone CID 56843046 physical properties SMILES | 1 result, 1 selected |
selection rationaleselection rationaleChemical identity verification; physical properties | |||
Research document (raw, unedited pipeline output)
# Research Output: Butylone (PSX-0124)
*Research conducted: 2026-05-03*
*Provenance ID: 06b6a09f-833e-4fe1-bb84-4ee9f54dad20*
---
## Chemical Identity
**PubChem CID:** 56843046 (api_verified via PubChem lookup)
**IUPAC name:** 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
**Molecular formula:** C₁₂H₁₅NO₃ (free base)
**Molecular weight:** 221.25 g/mol (free base)
**InChIKey:** CGKQZIULZRXRRJ-UHFFFAOYSA-N
**CAS number:** 17762-90-2 (hydrochloride salt). A free-base CAS is not prominently listed in accessible databases; the HCl salt is the commercially distributed form.
**SMILES (derived from IUPAC name):** `CCC(NC)C(=O)c1ccc2c(c1)OCO2`
*(Note: The PubChem API tool did not return a SMILES string directly. The SMILES above is derived from the verified IUPAC name and confirmed molecular formula. Flagged for editorial verification.)*
**HCl salt properties** [Ref 22]:
- Molecular formula (HCl salt): C₁₂H₁₆ClNO₃
- Molecular weight (HCl): 257.71 g/mol
- Melting point: 223–228°C
- LogP: 1.34
- Vapor pressure: 1.68 × 10⁻⁶ mmHg at 25°C
**Stereochemistry:** Butylone possesses one chiral center at carbon-2 of the butanone chain. The InChIKey suffix "UHFFFAOYSA" indicates no defined stereochemistry in the canonical record — it is commercially distributed and studied as a racemic mixture. No enantioselective pharmacological studies for butylone have been published in accessible literature. Stereochemical data for the individual enantiomers remains a research gap (see mephedrone for comparison: Philogene-Khalid et al. 2017 demonstrated significant stereoselective differences in reinforcing properties for that compound [Ref 12]).
**Seed data discrepancies:**
- Brief lists no PubChem CID, SMILES, molecular formula, or molecular weight — all now confirmed above.
- IUPAC name in brief ("1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one") is correct and api_verified.
---
## Pharmacology
### Mechanism of Action
Butylone acts primarily at the monoamine transporters — the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) — with a mixed inhibitor/substrate profile that distinguishes it pharmacologically from both pure stimulants and pure entactogens.
**At DAT:** Saha et al. (2019 [Ref 1]) characterize butylone as a **DAT blocker** (uptake inhibitor) rather than a releasing substrate, classifying it in the cocaine-like mechanistic category at the dopamine transporter. This is confirmed by Eshleman et al. (2013 [Ref 6]), who describe butylone as a "lower affinity uptake inhibitor" at hDAT compared to mephedrone and methylone.
**At SERT:** Saha et al. (2019 [Ref 1]) characterize butylone as a **5-HT transporter substrate**, meaning it acts as a releaser at SERT rather than a simple blocker. Simmler et al. (2012 [Ref 7]) similarly report that butylone induces 5-HT release similar to MDMA in addition to acting as a non-selective monoamine uptake inhibitor. This dual profile — DAT blocker, SERT substrate — explains butylone's mixed stimulant/entactogen character.
**Note on conflicting characterizations:** Simmler et al. (2012 [Ref 7]) classify butylone as a "non-selective monoamine uptake inhibitor similar to cocaine," while also noting 5-HT release. The Saha et al. (2019 [Ref 1]) paper focuses more specifically on butylone and pentylone and provides finer-grained mechanistic resolution. Both papers are primary pharmacology research; the Saha characterization (DAT blocker / SERT substrate) should be considered the more precise and recent account. **[FLAG: Generation agent should note this mechanistic nuance when describing mechanism of action.]**
**At NET:** Described as an uptake inhibitor at hNET (Eshleman et al. 2013 [Ref 6]). Unlike mephedrone and methylone, butylone does not robustly release preloaded [³H]norepinephrine in superfusion assays at hNET. Eshleman et al. (2013) characterize it as a "lower affinity" inhibitor across all three transporters compared to the more potent cathinones.
**5-HT₂A receptor:** López-Arnau et al. (2012 [Ref 2]) found that butylone's hyperlocomotor effects in mice could be blocked by ketanserin (5-HT₂A antagonist) or haloperidol (D2 antagonist), suggesting that both serotonin 5-HT₂A receptor activation and dopaminergic pathways mediate its behavioral effects. Its affinity for 5-HT₂A receptors is described as similar to MDMA.
**Other receptors:** Eshleman et al. (2013 [Ref 6]) report:
- 5-HT₁A: low potency partial agonist
- 5-HT₂A: antagonist (radioligand binding assay)
- 5-HT₂C: weak antagonist
- Sigma-1 receptor: high-nanomolar to mid-micromolar affinity
- Dopamine receptors (D1/D2): no measurable affinity
- hVMAT2: low uptake inhibitory potency and low release efficacy
**TAAR1 (trace amine-associated receptor 1):** Simmler et al. (2012 [Ref 7]) note that non-β-keto amphetamines are TAAR1 ligands but cathinones are not; butylone as a cathinone is not a TAAR1 agonist.
**Blood-brain barrier permeability:** Simmler et al. (2012 [Ref 7]) report high BBB permeability for butylone in an in vitro model, consistent with its CNS activity.
### Specific Pharmacological Values
Published specific Ki or IC₅₀ values for butylone at DAT/SERT/NET are contained in Simmler et al. (2012 [Ref 7]) and Saha et al. (2019 [Ref 1]), but the full numeric tables were not accessible via open-access retrieval during this research run. The following qualitative hierarchy is established across sources:
- Butylone's affinity at all three transporters is **lower** than methylone and mephedrone (Eshleman 2013 [Ref 6])
- Butylone's DAT/SERT selectivity ratio places it between methylone (more SERT-selective) and MDPV (DAT-selective) (Simmler 2012 [Ref 7])
- Class-level SERT:DAT ratio for butylone is estimated as roughly balanced (non-selective) with preferential SERT substrate activity vs. DAT blocking activity
**[FLAG for generation agent: Exact Ki/IC₅₀ values at DAT, SERT, NET are not confirmed from accessible primary source text. The Simmler 2012 and Saha 2019 papers contain this data — recommend accessing full text via institutional access for specific numbers before publishing.]**
### In Vivo Pharmacology
López-Arnau et al. (2012 [Ref 2]) tested butylone in mice at 5–25 mg/kg i.p.:
- Dose-dependent hyperlocomotion
- Blocked by ketanserin (5-HT₂A antagonist) and haloperidol
- Inhibited [³H]5-HT and [³H]dopamine uptake in rat synaptosomes
No rat or primate in vivo microdialysis studies specifically for butylone were identified in accessible literature. Microdialysis studies exist for methylone and mephedrone (Baumann et al. 2012 [Ref 17]) but not for butylone specifically.
### Hepatotoxicity and CYP450 Involvement
Roque Bravo et al. (2021 [Ref 4]) conducted the most detailed mechanistic hepatotoxicity study for butylone:
- **EC₅₀ in primary rat hepatocytes (PRH):** 1.21 mM
- For comparison: 3,4-DMMC EC₅₀ = 0.158 mM (more toxic); buphedrone EC₅₀ = 1.57 mM (less toxic)
- PRH was more sensitive than HepaRG and HepG2 cell lines
- **CYP450 inhibitors INCREASED butylone toxicity** — this is mechanistically important: CYP450 metabolism produces toxic metabolites (bioactivation), not detoxification. Co-exposure with CYP inhibitors in clinical settings may paradoxically reduce hepatotoxicity.
- Mechanisms identified: oxidative stress, mitochondrial membrane potential disruption, apoptosis (caspase-dependent), necrosis, autophagy (acidic vesicular organelle increase)
This finding has important clinical implications: drugs that inhibit CYP450 enzymes (e.g., certain SSRIs, antifungals) may reduce the metabolic generation of toxic butylone metabolites, but the overall interaction profile remains complex.
### Neurotoxicity
Leong et al. (2020 [Ref 11]) tested butylone, pentylone, and MDPV in differentiated SH-SY5Y human neuronal cells:
- Dose-dependent neurotoxicity at 24h
- Significant ROS production (p < 0.0001)
- Decreased mitochondrial bioenergetics
- Increased intracellular Ca²⁺
- Caspase 3 and 7 activation → mitochondrial apoptosis pathway
- EC₁₅ and EC₄₀ doses were assessed
**Limitation:** These are in vitro data using a human neuroblastoma cell line. No in vivo neurotoxicity studies for butylone have been published.
### Pharmacokinetics
**No published human pharmacokinetic studies for butylone exist.** The following is inferred from available data:
**Metabolism:** Uralets et al. (2014 [Ref 9]) conducted the largest human urinary excretion study for cathinones. Butylone, as a methylenedioxy-substituted cathinone, was found to metabolize by **carbonyl reduction to a lesser extent** than non-methylenedioxy cathinones (which undergo extensive carbonyl reduction to substituted ephedrines). Butylone is **best detected as the parent compound** in free urine fractions, rather than via metabolites. This pattern is shared with methylone and ethylone.
**CYP450 involvement:** Roque Bravo et al. (2021 [Ref 4]) confirmed CYP450 involvement in butylone metabolism using selective CYP450 inhibitors in hepatocytes, but did not identify the specific CYP isoforms responsible. No published data specifying CYP2D6, CYP3A4, or other isoforms for butylone is available.
**Half-life, bioavailability, Tmax:** Not published for butylone. Seed data states a tolerance half-life of 5 days and full reset at 1.5 weeks — these appear to be class-level estimates or community-derived, not from published pharmacokinetic studies. **[FLAG: Tolerance timeline is unverified against published sources.]**
---
## History
**First synthesis:** Butylone was first synthesized in 1967 by Koeppe, Ludwig, and Zeile — the same researchers who produced a series of β-keto MDMA analogs. This is documented in an obscure 1967 publication (pre-digital, **unverifiable** via API tools) referenced in Wikipedia and secondary sources. The compound is the β-keto analogue of MBDB (N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine), which is itself an MBDB-series entactogen described by Alexander Shulgin.
**Market emergence:** Butylone appeared on research chemical and designer drug markets approximately in **2005**, initially sold legally as a "legal high" under product names referencing its chemical identity (bk-MBDB) or as a generic bath salt component. Erowid contemporaneous records describe it as "extremely uncommon with nearly no history of human use" at that time.
**First formal research:** The first formal pharmacological and metabolic research on butylone appears to have been conducted circa 2009–2012, coinciding with the global "bath salts" epidemic. The first major pharmacology papers were published in 2012 (López-Arnau, Simmler), alongside the first reported human death (Warrick, 2012).
**Research chemical context:** Baumann et al. (2012 [Ref 17]), which included Alexander Shulgin as a co-author, characterized the broader class of methylenedioxy cathinones (mephedrone, methylone) as substrates for monoamine transporters analogous to MDMA. This pharmacological framework contextualizes butylone's development as part of the MDMA-analog research chemical tradition.
**Regulatory history:** See Legal Status section.
---
## Subjective Effects
**No controlled human clinical studies have been conducted for butylone.** The following is drawn from:
1. Published case reports documenting clinical presentations
2. Class-level inference from MDMA/methylone pharmacology
3. Community experience noted in harm reduction resources (no citable primary source)
The single most pharmacologically informative account of acute butylone effects comes from the Warrick (2012 [Ref 5]) case report, which documents pathological rather than recreational effects: fever 41.8°C, tachycardia (158 bpm), tachypnea, diaphoresis, tremors, hyperreflexia, bilateral ankle clonus, and coma — consistent with severe serotonin syndrome following a massive dose (~106 mg butylone + ~844 mg methylone).
Erowid describes effects as "similar to but milder than those of MDMA" (web_retrieved, low evidential weight). The effects taxonomy in the brief (empathy enhancement, stimulation, music enhancement, touch enhancement, warmth) is consistent with butylone's entactogen pharmacology but is not supported by controlled human data.
**Duration data from seed data** (onset 15–60 min oral; total 3–5 hours) is plausible given the compound's lipophilicity (LogP 1.34) and comparison with methylone (similar pharmacokinetic profile expected), but no published human pharmacokinetic data confirms these values. **[FLAG: Duration data is editorial or community-derived, not from controlled studies.]**
---
## Safety & Toxicity
### Published Human Case Reports
**Case 1 — Lethal serotonin syndrome (Warrick et al. 2012 [Ref 5]):**
- Patient: 24-year-old healthy female
- Setting: Concert, ingested two capsules labeled "Ecstasy"
- Drug content (capsule analysis): 422 mg methylone + 53 mg butylone per capsule (~844 mg methylone + ~106 mg butylone total estimated ingestion)
- Clinical presentation: Coma on arrival, temperature 41.8°C, HR 158 bpm, RR 34 bpm, diaphoresis, tremors, hyperreflexia, bilateral ankle clonus (meets Hunter criteria for serotonin syndrome)
- Treatment: Diazepam 10 mg IV, fluid resuscitation, mechanical ventilation, external cooling
- Course: Pulseless electrical activity arrest at 10 hours post-admission; spontaneous circulation restored; DIC, ARDS, multi-organ failure
- Death: 48 hours after presentation
- Medical examiner cause of death: Serotonin syndrome secondary to methylone and butylone
- Pathological findings: Coagulopathy, fatty liver, anoxic encephalopathy
- **Significance: First reported human death involving butylone; first known human ingestion report for butylone**
**Case 2 — Fatal overdose, isolated butylone (Rojek et al. 2012 [Ref 3]):**
- Patient: 21-year-old male
- Circumstance: Suicide via deliberate ingestion of preparation called "Amphi-bi-a" containing bk-MBDB
- Clinical course: ~4-hour hospitalization before death
- Toxicological findings: Blood concentration 20 mg/L; liver concentration 33 mg/kg
- These concentrations are described as "extremely high" by the authors
- Context: Poland, forensic case
### Toxic Concentrations
The two case reports above represent the only published human toxicology data for butylone specifically:
- Blood: 20 mg/L (fatal, isolated butylone; Rojek 2012 [Ref 3])
- Note that Zaami et al. (2018 [Ref 10]) note that most cathinone-related fatalities rarely exceed 1 mg/L in postmortem fluids; the Rojek case at 20 mg/L represents an unusually high concentration consistent with intentional overdose.
- Elliott & Evans (2014 [Ref 18]) note that for cathinones generally, "blood concentration does not appear to predict outcome regarding fatalities or impairment" (Marinetti & Antonides 2013 [Ref 19]).
### In Vitro Toxicity Data (Animal/Cell Models)
| Model | EC₅₀ | Reference |
|-------|-------|-----------|
| Primary rat hepatocytes | 1.21 mM | Roque Bravo et al. 2021 [Ref 4] |
| HepaRG (human hepatocyte cell line) | Higher than PRH | Roque Bravo et al. 2021 [Ref 4] |
| HepG2 (human hepatoma) | Higher than PRH | Roque Bravo et al. 2021 [Ref 4] |
| SH-SY5Y (differentiated human neuroblastoma) | EC₁₅/EC₄₀ assessed | Leong et al. 2020 [Ref 11] |
All animal/cell data — species noted.
### LD₅₀
No published LD₅₀ for butylone in any species. The exact toxic dose in humans is unknown; seed data correctly notes this. Seed data assessment is confirmed.
### Cardiovascular and Sympathomimetic Risks
Class-level data (Debruyne et al. 2014 [Ref 21]; Prosser & Nelson 2011 [Ref 8]; Luethi & Liechti 2020 [Ref 20]): cathinones as a class cause tachycardia, hypertension, hyperthermia, and in severe cases rhabdomyolysis, metabolic acidosis, and multi-organ failure. These effects are mediated through central and peripheral monoamine release/reuptake inhibition.
### Psychological Risks
Documented in case series and user surveys (Ashrafioun et al. 2016; Zimmerman et al. 2019 [Refs from PubMed search batch]): anxiety, paranoia, agitation, psychosis, tolerance development, negative consequences of use.
---
## Harm Reduction
No butylone-specific harm reduction guidelines exist in published literature. The following is derived from class-level cathinone evidence and the specific case reports:
**Testing:** Butylone may be sold as or mixed with MDMA/Ecstasy (confirmed by Warrick 2012 case [Ref 5]). Reagent testing is essential — butylone will react with Marquis reagent (produces a color change consistent with cathinone/MDxx class compounds, distinct from pure amphetamines). Fentanyl test strips may be warranted given polydrug supply contexts.
**Temperature regulation:** The lethal Warrick case involved hyperthermia to 41.8°C. Maintaining cool environment, avoiding exertion, and adequate hydration (without overhydration) are indicated.
**Serotonin syndrome recognition:** Symptoms include hyperthermia, tachycardia, clonus, tremor, hyperreflexia, and agitation. Treatment is supportive: benzodiazepines for agitation and seizures, active cooling, cyproheptadine (5-HT₂A antagonist) has been used; avoid antipsychotics with anticholinergic properties that worsen hyperthermia.
**Drug combinations:** Combining with any serotonergic agents is high-risk. The Warrick case demonstrates that combining with methylone at even moderate doses can be lethal. Tramadol is flagged as particularly dangerous due to its serotonergic activity.
**Detection:** Butylone is not detected by standard immunoassay urine drug screens. Specific LC-MS/MS or GC-MS methods are required (Marinetti & Antonides 2013 [Ref 19]; Uralets et al. 2014 [Ref 9]).
**No specific antidote exists** (Debruyne et al. 2014 [Ref 21]).
---
## Tolerance & Dependence
No published human studies on butylone tolerance or dependence exist.
**Class-level evidence:** Animal studies for cathinones as a class (Watterson & Olive 2014; cited in [Ref 12]) demonstrate reinforcing properties via self-administration. Methylone shows self-administration in rodents with high break points. No specific butylone self-administration or conditioned place preference studies were identified.
**Seed data values:**
- Tolerance buildup: "develops with prolonged and repeated use" — plausible (class inference), unverified for butylone
- Half-life: 5 days — **unverified**, not from published pharmacokinetic data for butylone specifically
- Full reset: 1.5 weeks — **unverified**, appears to be community consensus or editorial estimate
- Cross-tolerances: dopamine, stimulant — plausible (DAT activity), unverified
- Physical dependence: moderate — **unverified**
- Psychological dependence: moderate — **unverified**
- Formation: "moderately addictive with a high potential for abuse" — plausible based on DAT activity and serotonergic profile; consistent with FDA/DEA Schedule I placement reasoning
**[FLAG: All tolerance and dependence values in seed data are unverified against published sources. These are class-level estimates. Flag for editorial review.]**
---
## Interactions
### Documented Interactions
**Methylone (combined) → Lethal serotonin syndrome [Ref 5]:**
The Warrick 2012 case report documents the first known death from combined methylone and butylone ingestion. Mechanism: additive serotonergic effects from two cathinones with serotonin-releasing and/or reuptake-inhibiting properties. Combined ingestion produces serotonin syndrome risk proportional to total serotonergic load.
### Seeded Interaction Claims and Evidence Review
**Tramadol: listed as "lethal" in seed data**
- No specific published case report of butylone + tramadol fatality was identified in this research.
- Tramadol is a weak opioid with serotonergic activity (SERT inhibitor, weak serotonin releaser). Its combination with serotonergic drugs (SSRIs, triptans, MAOIs, MDMA analogs) is well-documented to risk serotonin syndrome (general serotonin literature, not butylone-specific).
- The "lethal" classification is a class-level inference based on butylone's serotonergic mechanism + tramadol's serotonergic activity. It is not confirmed by a published butylone+tramadol case report.
- **[FLAG: "Lethal" severity for tramadol interaction is unverified against a specific butylone+tramadol published source. The risk is real (serotonergic mechanisms on both sides) but severity classification needs editorial review. Recommend "dangerous" with note on serotonin syndrome mechanism.]**
**MDMA: listed as "dangerous"**
- Supported by class-level pharmacology: MDMA + butylone would combine two serotonin-releasing/reuptake-inhibiting agents, greatly elevating serotonin syndrome risk. No specific published butylone+MDMA case report identified.
- Severity rating "dangerous" is consistent with available evidence.
**Alcohol: listed as "unknown"**
- No published data on butylone-alcohol interaction identified. Alcohol co-use is common among cathinone users (see epidemiology studies) but no specific interaction data exists.
- "Unknown" classification is appropriate.
### CYP450 Interaction Risk
Roque Bravo et al. (2021 [Ref 4]) demonstrated that CYP450 inhibitors increase butylone's hepatotoxicity in vitro. This implies that co-administration with CYP inhibitors (e.g., ketoconazole, fluoxetine, ritonavir) could increase hepatotoxic metabolite generation. However, this finding is from in vitro rat hepatocytes and has not been confirmed in human clinical settings.
---
## Legal Status
### United States
- **Temporary Schedule I:** March 7, 2014 (DEA, Federal Register 2014-04997) [Ref 15]
- **Permanent Schedule I:** March 1, 2017 (DEA, Federal Register 2017-03974) [Ref 16]
- **DEA code:** 7541
- Prior to March 2014, subject to the Federal Analogue Act as an amphetamine/cathinone analog; several US states had enacted state-level controls earlier (Virginia: Schedule I effective July 1, 2012; Kentucky: HR 481 2012; Vermont: 2012)
### United Kingdom
- **Class B** controlled substance under the Misuse of Drugs Act 1971
- Effective: **April 16, 2010** (S.I. 2010/1207, generic cathinone amendment)
- [Ref 14]
### China
- Category I psychotropic substance
- Effective: **September 2010**
- [Ref 14]
### Israel
- Controlled substance
- Effective: **2009** (earliest known national control)
- [Ref 14]
### Japan
- Classified as a "Designated Substance" (Shitei Yakubutsu)
- [Ref 14]
### Norway
- Controlled under analog legislation (Derivatbestemmelsen)
- [Ref 14]
### Slovakia
- Controlled: **March 1, 2011**
- [Ref 14]
### Finland
- Controlled: **December 2014**
- [Ref 14]
### Italy
- Listed in Table I of controlled substances
- [Ref 14]
### European Union
- No single EU-wide scheduling decision for butylone was confirmed in accessible sources. Butylone is not listed in the EU Council Decision framework for new psychoactive substances as a specifically named compound at time of research. It falls under national cathinone controls in various member states.
### Australia
- Listed in the Office of Drug Control (ODC) controlled substances database. Specific Schedule (likely Schedule 9 — Prohibited Substance) not confirmed in accessible sources during this research.
### Canada
- Canada-specific scheduling status not confirmed in accessible sources. Under the Controlled Drugs and Substances Act, butylone may fall under analog provisions, but no specific scheduling record was found.
---
## Clinical Trials
No clinical trials for butylone were identified on ClinicalTrials.gov. The search returned zero results for "butylone synthetic cathinone." This is expected given the substance's Schedule I status (US), lack of any therapeutic application, and the absence of research interest in butylone as a therapeutic candidate.
---
## Community Feedback Analysis
No community feedback was submitted in Part A2 of the brief. No community feedback items to investigate or report.
---
## Gaps & Flags
### Safety-Critical Flags (Require Editorial Review)
1. **[FLAG — INTERACTION SEVERITY]** Tramadol listed as "lethal" in seed data. No specific published butylone+tramadol case report identified. Risk is real (additive serotonergic mechanisms) but "lethal" severity classification for this specific combination is not confirmed by published evidence. Recommend downgrading to "dangerous" with explanation, or leaving flagged pending editorial review.
2. **[FLAG — DOSE/DURATION DATA]** All dose range values and duration data in seed data are unverified against published controlled human studies (none exist for butylone). Dose values appear to be editorial estimates or community consensus. The only human ingestion data is from overdose cases. These should remain flagged as community-derived/editorial.
3. **[FLAG — TOLERANCE/DEPENDENCE]** All tolerance and dependence values (half-life 5 days, reset 1.5 weeks, cross-tolerances) are unverified against published sources. Class-level inference only.
4. **[FLAG — SMILES]** PubChem API tool did not return SMILES. Derived SMILES `CCC(NC)C(=O)c1ccc2c(c1)OCO2` from IUPAC name — verify before publishing.
5. **[FLAG — HEPATOTOXICITY MECHANISM]** CYP450 inhibitors increase butylone toxicity (Roque Bravo 2021). This counter-intuitive finding (metabolic activation, not detoxification) has implications for drug interaction listings. No CYP isoform identified.
### Verified Absences
- No published human pharmacokinetic studies (T½, bioavailability, Tmax, Cmax)
- No specific Ki or IC₅₀ values confirmed from accessible full-text sources (behind paywall in Simmler 2012, Saha 2019)
- No published LD₅₀ in any species
- No published in vivo neurotoxicity studies for butylone
- No butylone-specific self-administration, CPP, or ICSS animal studies
- No enantioselective pharmacology for butylone
- No controlled human clinical studies of any kind
- No published data on subjective effects in human volunteers
- Original 1967 Koeppe/Ludwig/Zeile synthesis paper: unverifiable (pre-digital)
- EU-wide scheduling: not confirmed
- Canada/Australia: specific schedule classification not confirmed
### Source Conflicts
- **Simmler 2012 vs. Saha 2019 on DAT mechanism:** Simmler classifies butylone as a "non-selective uptake inhibitor" (cocaine-like at DAT); Saha characterizes it as a "DAT blocker but 5-HT transporter substrate," which is mechanistically similar but emphasizes the SERT substrate distinction. Both are consistent: butylone blocks DAT (uptake inhibitor) and releases 5-HT via SERT (substrate mechanism). Generation agent should synthesize both characterizations.
### Structural Analogy Reliance
The following sections rely primarily on class-level or structural analog inference rather than butylone-specific data:
- Subjective effects description
- Duration data
- Tolerance/dependence values
- Tramadol interaction severity
- MDMA interaction severity
- All cardiovascular/psychiatric adverse effect descriptions beyond the two case reports